Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Research analysts at HC Wainwright upped their Q3 2027 earnings per share estimates for Adherex Technologies in a note issued to investors on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.28 per share for the quarter, up from their previous estimate of $0.25. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Adherex Technologies' current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Adherex Technologies' Q4 2027 earnings at $0.33 EPS.
Adherex Technologies (NASDAQ:FENC - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.02. Adherex Technologies had a return on equity of 8.96% and a net margin of 2.52%. The business had revenue of $19.61 million for the quarter, compared to analysts' expectations of $18.87 million.
Several other equities research analysts have also recently weighed in on the company. Zacks Research upgraded Adherex Technologies from a "hold" rating to a "strong-buy" rating in a research report on Thursday, November 12th. Wedbush boosted their price objective on shares of Adherex Technologies from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Wednesday, August 12th. B. Riley Financial reaffirmed a "buy" rating and set a $19.00 price objective (up from $18.00) on shares of Adherex Technologies in a research note on Monday. Finally, Weiss Ratings raised shares of Adherex Technologies from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Adherex Technologies has a consensus rating of "Buy" and a consensus price target of $17.50.
Read Our Latest Analysis on FENC
Adherex Technologies Stock Down 1.8%
FENC stock opened at $13.33 on Thursday. The firm has a market capitalization of $469.48 million, a PE ratio of 194.00 and a beta of 1.29. Adherex Technologies has a twelve month low of $5.65 and a twelve month high of $13.85. The stock has a 50-day simple moving average of $10.71 and a two-hundred day simple moving average of $9.45.
Insider Transactions at Adherex Technologies
In other news, CFO Robert Andrade sold 75,000 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total transaction of $883,500.00. Following the completion of the transaction, the chief financial officer owned 217,675 shares of the company's stock, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of the company's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the transaction, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. This trade represents a 55.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 10.73% of the company's stock.
Adherex Technologies Company Profile
(
Get Free Report)
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adherex Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adherex Technologies wasn't on the list.
While Adherex Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.